March 27th 2024
A posthoc analysis of two phase 3 trials identified multiple independent factors associated with better response to vadadustat in patients with anemia.
No Increased Risk of Fracture with SGLT2 Inhibitors in Diabetic Kidney Disease, Study Finds
May 27th 2022Analysis of data from more than 75k patients with diabetes in Canada suggests use of SGLT2 inhibitors was not associated with an increased fracture risk compared with DPP-4 inhibitors among patients with diabetic kidney disease.
Initial eGFR Dips Common with SGLT2 Inhibitors, Not Typically Associated with Negative Outcomes
April 25th 2022An analysis of the DAPA-HF trial provides insight into the occurrence of eGFR dips in the first 14 days following initiation of therapy with an SGLT2 inhibitor and their association with long-term outcomes.
Finerenone Provides Consistent Benefit for Reducing CV Risk, Regardless of CVD History
April 9th 2022A prespecified analysis of FIDELITY presented at ACC.22 details the effects of finerenone on reducing cardiovascular risk based on whether or not patients had a history of atherosclerotic cardiovascular disease at baseline.
Finerenone Reduces CV Risk in T2D and CKD, Regardless of ASCVD History
April 7th 2022A prespecified analysis of FIDELITY details the effects of finerenone against placebo therapy for reducing the risk of cardiovascular events based on history of ASCVD among patients with type 2 diabetes and chronic kidney disease.
Sotagliflozin Reduces Stroke, MI, and CV Death, Regardless of CVD History
April 4th 2022Deepak Bhatt, MD, MPH, breaks down data from the SCORED trial presented at ACC.22, which demonstrated sotagliflozin provided significant benefit in terms of reducing total MACE, total MI, and total stroke, regardless of whether a patient had a history of cardiovascular disease.
Deepak Bhatt, MD, MPH: Estimating the Potential US Patient Population for Finerenone
April 4th 2022We sat down with Deepak Bhatt, MD, MPH, at ACC.22 to discuss a study he took part in assessing the potential patient population of finerenone using eligibility criteria from FIDELIO-DKD and FIGARO-DKD against information from NHANES.
GLP-1 RAs Could Lower Mortality Risk in Type 2 Diabetes with Advanced CKD
March 8th 2022A retrospective cohort study suggests use of GLP-1 RAs was associated with a 21% reduction in risk of all-cause mortality in patients with type 2 diabetes and advanced-stage chronic kidney disease compared with DPP-4 inhibitors.
APOL1 Testing Can Spur Improved Blood Pressure Control in African Americans with Hypertension
March 8th 2022A randomized trial comparing the effects of immediate testing and disclosure versus delayed testing, results suggest disclosing results of APOL1 testing led to reductions in blood pressure and meaningful lifestyle changes among patients with hypertension.
FDA Issues CRL for Bardoxolone Methyl in CKD Caused By Alport Syndrome
February 28th 2022The CRL for bardoxolone methyl for treatment of CKD caused by Alport syndrome comes less than 3 months after an FDA advisory committee voted unanimously against approval of Reata Pharmaceutical's once-daily, orally administered activator of Nrf2.
Bardoxolone Rejected by FDA for CKD Caused by Alport Syndrome
February 26th 2022Announced by Reata Pharmaceuticals on February 25, the Complete Response Letter from the FDA for bardoxolone methyl comes a little over 2 months after an FDA advisory committee voted unanimously against approval of the once-daily, orally administered activator of Nrf2.
Study Details Causal Effect of Obesity on Diabetic Nephropathy
February 22nd 2022Data from an analysis of more than 150,000 patients suggests increased BMI was associated with more than a 3-fold increase in odds of diabetic nephropathy in patients with type 2 diabetes, but this effect was more apparent in women who experienced a 14-fold increase in odds of diabetic nephropathy.
Assisted Reproductive Technologies Could Increase Risk of Arrhythmia, Kidney Injury
February 22nd 2022An analysis of data from the National Inpatient Sample suggests pregnancies conceived by assisted reproductive technology carried a 1.7- and 2.5-fold increase in risk for arrhythmia and acute kidney injury compared to those conceived without ART.
Study Raises Alarm Over Risk of Chronic Kidney Disease, Rising Obesity Rates in Type 1 Diabetes
January 26th 2022An analysis of data from more than 135k patients with type 1 and type 2 diabetes indicates the age-adjusted rate of chronic kidney disease was greater in type 1 diabetes and also sheds light on the rising rate of obesity in type 1 diabetes.
Nutrition Information Hard to Find, Access for Patients with Kidney Disease
January 19th 2022A recent study published in the Journal of the American Society of Nephrology suggests patients with chronic kidney disease have little access to reliable information related to nutrition for patients with chronic kidney disease.
Deepak Bhatt, MD, MPH: Sotagliflozin Provides Consistent Benefit Across Spectrum of Kidney Function
November 14th 2021Deepak Bhatt, MD, MPH, discusses the results of a pooled analysis of the SOLOIST and SCORED trials assessing effects of sotagliflozin based on baseline eGFR among patients included in the trials.
CLICK Trial: Chlorthalidone Reduces BP in Chronic Kidney Disease and Uncontrolled Hypertension
November 10th 2021Data from the CLICK trial presented at Kidney Week 2021 demonstrates chlorthalidone reduced systolic blood pressure by 11 mmHg over a 12-week treatment period among a patient population with stage 4 CKD and uncontrolled hypertension.
Dapagliflozin Slows Rate of Kidney Function Decline, Regardless of Diabetes Status
November 9th 2021Data from a prespecified analysis of DAPA-CKD presented at Kidney Week 2021 provides insight into the effects of dapagliflozin use on the rate of kidney function decline based on the presence of type 2 diabetes from the trial.
Risk Model Suggests SGLT2 Inhibitors Could Reduce CV, Renal Risk in Type 1 Diabetes
November 8th 2021Using the Steno Type 1 Risk Engine, a team from Denmark conducted a study suggesting SGLT2 inhibition could lower risk of cardiovascular disease and end-stage kidney disease in patients with type 1 diabetes.
FIDELITY: Finerenone Slows CKD Progression Across Full Spectrum of Severity
November 5th 2021Data from the FIDELITY analysis suggests use of finerenone was associated with a significant 20% reduction in end-stage kidney disease as well as reductions in all nonfatal kidney end points included in the study's composite kidney outcome.